Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025
Nuvation Bio (NYSE: NUVB) has announced it will present new nonclinical data for taletrectinib in ROS1-positive non-small cell lung cancer (NSCLC) at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Chicago (April 25-30, 2025).
The presentation will focus on taletrectinib's role as a next-generation selective ROS1 inhibitor and its effectiveness in inhibiting growth of ROS1 wild-type and ROS1-G2032R xenografts. Dr. Hitisha Patel, Director of Research at Nuvation Bio, will present the findings on April 29, 2025, during the Kinase and Phosphatase Inhibitors 3 session.
Nuvation Bio (NYSE: NUVB) ha annunciato che presenterà nuovi dati non clinici per taletrectinib nel cancro polmonare non a piccole cellule (NSCLC) positivo per ROS1 al prossimo Meeting Annuale dell'American Association for Cancer Research (AACR) a Chicago (25-30 aprile 2025).
La presentazione si concentrerà sul ruolo di taletrectinib come inibitore selettivo di nuova generazione per ROS1 e sulla sua efficacia nell'inibire la crescita di xenotrapianti ROS1 wild-type e ROS1-G2032R. La Dott.ssa Hitisha Patel, Direttore della Ricerca di Nuvation Bio, presenterà i risultati il 29 aprile 2025, durante la sessione Kinase and Phosphatase Inhibitors 3.
Nuvation Bio (NYSE: NUVB) ha anunciado que presentará nuevos datos no clínicos sobre taletrectinib en cáncer de pulmón no microcítico (NSCLC) positivo para ROS1 en la próxima Reunión Anual de la American Association for Cancer Research (AACR) en Chicago (25-30 de abril de 2025).
La presentación se centrará en el papel de taletrectinib como un inhibidor selectivo de ROS1 de nueva generación y su efectividad en la inhibición del crecimiento de xenoinjertos ROS1 wild-type y ROS1-G2032R. La Dra. Hitisha Patel, Directora de Investigación en Nuvation Bio, presentará los hallazgos el 29 de abril de 2025, durante la sesión de Inhibidores de Quinasa y Fosfatasa 3.
누베이션 바이오 (NYSE: NUVB)는 탈레트렉티닙에 대한 새로운 비임상 데이터를 ROS1 양성 비소세포 폐암(NSCLC)에서 발표할 것이라고 발표했습니다. 이는 오는 미국 암 연구 협회(AACR) 연례 회의에서 진행될 예정이며, 일시는 시카고(2025년 4월 25-30일)입니다.
발표는 탈레트렉티닙의 차세대 선택적 ROS1 억제제로서의 역할과 ROS1 와일드타입 및 ROS1-G2032R 이종이식의 성장 억제 효과에 초점을 맞출 것입니다. 누베이션 바이오의 연구 책임자인 히티샤 파텔 박사가 2025년 4월 29일 퀴나제 및 포스파타제 억제제 3 세션에서 연구 결과를 발표할 예정입니다.
Nuvation Bio (NYSE: NUVB) a annoncé qu'il présentera de nouvelles données non cliniques sur taletrectinib dans le cancer du poumon non à petites cellules (NSCLC) positif pour ROS1 lors de la prochaine Réunion Annuelle de l'American Association for Cancer Research (AACR) à Chicago (25-30 avril 2025).
La présentation mettra l'accent sur le rôle de taletrectinib en tant qu'inhibiteur sélectif de ROS1 de nouvelle génération et son efficacité à inhiber la croissance des xénogreffes ROS1 wild-type et ROS1-G2032R. La Dr Hitisha Patel, Directrice de la Recherche chez Nuvation Bio, présentera les résultats le 29 avril 2025, lors de la session Inhibiteurs de Kinase et de Phosphatase 3.
Nuvation Bio (NYSE: NUVB) hat angekündigt, dass es neue nichtklinische Daten zu Taletrectinib bei ROS1-positivem nicht-kleinzelligem Lungenkrebs (NSCLC) auf der bevorstehenden Jahrestagung der American Association for Cancer Research (AACR) in Chicago (25.-30. April 2025) präsentieren wird.
Die Präsentation wird sich auf die Rolle von Taletrectinib als selektiven ROS1-Inhibitor der nächsten Generation und dessen Wirksamkeit bei der Hemmung des Wachstums von ROS1-Wildtyp- und ROS1-G2032R-Xenotransplantaten konzentrieren. Dr. Hitisha Patel, Forschungsleiterin bei Nuvation Bio, wird die Ergebnisse am 29. April 2025 während der Sitzung „Kinase und Phosphatase-Inhibitoren 3“ präsentieren.
- None.
- None.
Presentation Overview:
Title: Taletrectinib, a next generation selective ROS1 inhibitor, inhibits growth of ROS1 wild-type and ROS1-G2032R xenografts
Presenter: Hitisha Patel, Ph.D., Director of Research, Nuvation Bio
Session Category: Experimental and Molecular Therapeutics
Session Title: Kinase and Phosphatase Inhibitors 3
Date: Tuesday, April 29, 2025
Session Time and Location: 2:00 – 5:00 p.m. CT / 3:00 – 6:00 p.m. ET; Poster Section 20
Poster Board Number: 22
Abstract Number: 5612
The materials will be made available in the Publications section of Nuvation Bio’s website after the presentation.
About Taletrectinib
Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib is being evaluated for the treatment of patients with advanced ROS1+ NSCLC in two Phase 2 single-arm pivotal studies: TRUST-I (NCT04395677) in
Based on pooled results of the TRUST-I and TRUST-II clinical studies, the
About Nuvation Bio
Nuvation Bio is a global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates. Nuvation Bio’s programs include taletrectinib (ROS1), safusidenib (mIDH1), NUV-1511 (DDC), and NUV-868 (BET). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250325813594/en/
Nuvation Bio Investor Contact:
ir@nuvationbio.com
Nuvation Bio Media Contact:
media@nuvationbio.com
Source: Nuvation Bio Inc.
FAQ
What new data will Nuvation Bio (NUVB) present at AACR 2025?
When and where will NUVB present the taletrectinib data at AACR 2025?
What type of cancer is taletrectinib targeting for NUVB?
Who will present the taletrectinib data for NUVB at AACR 2025?
